Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

CK Lee*1, MR Stockler1,2, AS Coates1,3, V Gebski1, SJ Lord1 and RJ Simes1,2 on behalf of Australian New Zealand Breast Cancer Trials Group

1NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, Australia; 2Sydney Cancer Centre – Royal Prince Alfred and Concord Hospitals, Sydney, NSW, Australia; 3International Breast Cancer Study Group, Bern, Switzerland

BACKGROUND: Baseline health-related quality of life (QL) is associated with survival in advanced breast cancer. We sought to identify patients who were less likely to respond to chemotherapy and at greater risk of toxicity on the basis of their QL.

METHODS: We used data from three advanced breast cancer trials in which patients (n = 378) were treated with cyclophosphamide, methotrexate and 5-fluorouracil. Patients self-rated their QL using LASA scales for physical well-being (PWB), mood, pain, nausea/vomiting, appetite and overall QL. Multivariable regression models were constructed to compare overall survival (OS), objective tumour response (OTR), adverse events (AEs) and weight loss according to grouped QL scores.

RESULTS: Physical well-being, mood, appetite and overall QL were significant univariable predictors of OS. Physical well-being and appetite remained significant after adjustment for baseline biomedical factors. Poor PWB was associated with lower OTR (odds ratio (OR) = 0.21, 95% confidence interval (CI) 0.09–0.49), higher risk of non-haematological AEs (OR = 3.26, 95% CI 1.49–7.15) and greater risk of weight loss (OR 2.37, 95% CI 1.12–5.01) compared with good PWB.

CONCLUSIONS: In women with advanced breast cancer, PWB and appetite are predictors of chemotherapy response and toxicity as well as survival. Quality of life should be a routine clinical assessment to guide patient selection for chemotherapy and for stratification of patients in clinical trials.

British Journal of Cancer (2010) 102, 1341–1347. doi:10.1038/sj.bjc.6605649 www.bjcancer.com

Published online 13 April 2010

© 2010 Cancer Research UK

Keywords: quality of life; advanced breast cancer; treatment benefits; treatment toxicity
ANZ8101, activated in June 1982, was a two-by-two factorial RCT comparing the efficacy of doxorubicin and cyclophosphamide vs cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP), administered continuously vs intermittently (Coates et al, 1987). ANZ8614, activated in January 1988, was a two-arm RCT comparing the efficacy of mitoxantrone vs CMFP (Simes et al, 1994). ANZ0001, activated in June 2001, was a three-arm RCT comparing the efficacy of intermittent capecitabine vs continuous capecitabine vs CMFP (Stockler et al, 2007).

All three trials included a measurement of patients' self-reported QL at baseline. Investigation of QL as a predictor of treatment response or toxicity was not specified in the original trial protocols.

Patients

Patients had histologically confirmed breast carcinoma with measurable or evaluable recurrent or metastatic disease; adequate bone marrow, hepatic and renal function; and were available for follow-up. Patients were excluded if they had received cytotoxic chemotherapy for recurrent or metastatic disease or extensive radiotherapy, or had a history of other cancer, diabetes mellitus or cardiac failure.

Only patients assigned to the continuous CMFP in each of the three trials were included in the present analysis. Patients assigned to the intermittent CMFP arm of ANZ8101 were excluded from this study because this treatment arm was inferior to the CMFP regimen given continuously as in the other trials. All patients provided written informed consent for participation in the trials.

Treatments

In each of the three trials, CMFP was administered in 28-day cycles with oral cyclophosphamide (100 mg m\(^{-2}\)) daily for 14 days; intravenous methotrexate (40 mg m\(^{-2}\)) and intravenous 5-fluorouracil (600 mg m\(^{-2}\)) on days 1 and 8. Oral prednisone (40 mg m\(^{-2}\)) for first 14 days was routinely administered in patients from ANZ8101 and ANZ8614, and was optional in ANZ0001. All patients continued the initial chemotherapy regimen until disease progression, intolerance or unacceptable toxicity. Therapy beyond disease progression was at the discretion of the treating oncologist.

QL instruments

Patients self-reported their QL with five linear analogue self assessment (LASA) scales that measured physical well-being (PWB), mood, pain, nausea/vomiting and appetite (Priestman et al, 1977; Coates et al, 1993), and a single summative

| Table 1 Demographic characteristics and chemotherapy treatment profile |
|-----------------------------------------------|
| Characteristics                        | Overall n (%) | Good PWB* n (%) | Mid PWB* n (%) | Poor PWB* n (%) |
|-----------------------------------------------|
| Age > 60 years                             | 170 (45)       | 69 (47)         | 63 (44)        | 26 (41)         |
| Post-menopausal                            | 275 (73)       | 108 (74)        | 105 (74)       | 44 (70)         |
| Performance status                         |               |                |                |                |
| 0                                            | 123 (32)       | 69 (47)        | 37 (26)        | 11 (18)         |
| 1                                            | 153 (40)       | 54 (37)        | 69 (49)        | 21 (33)         |
| 2                                            | 74 (20)        | 16 (11)        | 30 (21)        | 21 (33)         |
| 3                                            | 25 (7)         | 7 (5)          | 6 (4)          | 8 (13)          |
| 4                                            | 2 (1)          | 0 (0)          | 0 (0)          | 2 (3)           |
| Extent of advanced cancer                  |               |                |                |                |
| Local or regional disease only              | 46 (12)        | 20 (14)        | 16 (11)        | 6 (9)           |
| Distant disease only                       | 186 (49)       | 73 (50)        | 70 (49)        | 32 (51)         |
| Locoregional and distant disease           | 146 (39)       | 53 (36)        | 56 (40)        | 25 (40)         |
| Disease-free interval > 2 years             | 208 (55)       | 78 (53)        | 74 (52)        | 38 (60)         |
| Hormone receptor status of primary breast tumour |
| ER+                                          | 151 (40)       | 63 (43)        | 56 (39)        | 25 (40)         |
| ER−                                          | 101 (27)       | 38 (26)        | 37 (26)        | 20 (32)         |
| PR+                                          | 115 (30)       | 47 (32)        | 43 (30)        | 18 (29)         |
| PR−                                          | 111 (29)       | 42 (29)        | 42 (30)        | 22 (35)         |
| Tissue sites of metastasis\(^{5}\)          |               |                |                |                |
| Liver                                        | 148 (39)       | 56 (38)        | 50 (35)        | 26 (41)         |
| Lung                                         | 123 (33)       | 32 (22)        | 59 (42)        | 25 (40)         |
| Brain                                        | 12 (3)         | 4 (3)          | 4 (3)          | 3 (5)           |
| Bone                                         | 256 (68)       | 96 (66)        | 99 (70)        | 44 (70)         |
| Prior adjuvant chemotherapy                 | 84 (22)        | 29 (20)        | 31 (22)        | 20 (32)         |
| Prior endocrine therapy                      | 292 (77)       | 108 (74)       | 108 (76)       | 54 (86)         |
| Haemoglobin ≤ 12 g d\(^{-1}\)               | 132 (35)       | 42 (29)        | 52 (37)        | 24 (38)         |
| Neutrophil > 7.5 × 10\(^{9}\) l\(^{-1}\)    | 46 (13)        | 14 (10)        | 16 (12)        | 9 (15)          |
| Bilirubin > 15 μmol l\(^{-1}\)              | 26 (7)         | 13 (9)         | 4 (3)          | 6 (10)          |
| Alkaline phosphatase > 125 IU l\(^{-1}\)    | 199 (54)       | 66 (46)        | 79 (57)        | 38 (62)         |
| Median number of cycles of CMFP treatment   | 5              | 6              | 5              | 3               |
| Range of cycles of CMFP treatment           | 1–25           | 1–25           | 1–21           | 1–14            |
| Percentage of cyclophosphamide received\(^{6}\) | 90%         | 92%           | 88%            | 83%             |
| Percentage of methotrexate received\(^{6}\) | 92%         | 96%           | 89%            | 81%             |
| Percentage of 5-fluorouracil received\(^{6}\) | 93%         | 95%           | 92%            | 81%             |

Abbreviations: CMFP = cyclophosphamide, methotrexate, 5-fluorouracil, prednisone chemotherapy; ER = oestrogen receptor; PR = progesterone receptor; PWB = physical well-being. \(^{a}\)Good PWB = LASA score 0–25; mid PWB = LASA score 26–65; poor PWB = LASA score 66–100. \(^{b}\)More than one site could have been involved, so percentages sum to more than 100%. \(^{c}\)The reported percentage is the median total dose of chemotherapy received as compared with the ideal dose calculated on the basis of the body-surface area.
LASA scale that measured overall QL (Spitzer et al., 1981). All scales were 100 mm long and scores range from 0 (best) to 100 (worst).

For the purpose of our analysis, scores for each QL scale were arbitrarily divided into three groups: good (0–25), mid (26–65) or poor (66–100). The categorisation was selected to be consistent with the cut-points used in a previous study (Coates et al., 1992).

**Treatment benefits**

Treatment benefits were evaluated by measuring OS, progression-free survival (PFS), objective tumour response (OTR) and improvement in baseline body weight. OS and PFS were measured from randomisation to the date of death or first documented disease progression respectively. OTR rate was measured as the proportion of patients with evaluable disease.

### Table 2 Univariable Cox regression analysis of survival (n = 378)

|                                | n (%)  | Hazard ratio (95% CI) | P-value |
|--------------------------------|--------|-----------------------|---------|
| **(A) Baseline demographic and clinical characteristics** |         |                       |         |
| Age > 60 (vs ≤ 60 years)       | 170 (45) | 1.29 (1.04–1.60)     | 0.02    |
| Post-menopausal                | 275 (73) | 1.21 (0.95–1.55)     | 0.12    |
| **Performance status (PS)**    |         |                       |         |
| PS 0                           | 132 (32) | 1.00 (0)              | 0.0007  |
| PS 1                           | 153 (40) | 1.40 (1.09–1.80)     |         |
| PS 2                           | 74 (20)  | 1.65 (1.21–2.23)     |         |
| PS3 & PS4                      | 27 (8)   | 2.08 (1.35–3.21)     |         |
| Disease-free interval > 2 years| 208 (55) | 1.19 (0.95–1.48)     | 0.13    |
| **Prior treatment**            |         |                       |         |
| Prior adjuvant chemotherapy    | 84 (22)  | 0.89 (0.68–1.17)     | 0.40    |
| Prior endocrine therapy        | 292 (77) | 1.20 (0.94–1.55)     | 0.15    |
| **Hormone receptor status**    |         |                       |         |
| ER−                            | 101 (27) | 1.00 (0)              | 0.01    |
| ER+                            | 151 (40) | 0.72 (0.54–0.94)     |         |
| ER unknown                     | 126 (33) | 1.00 (0.77–1.32)     |         |
| PR−                            | 111 (29) | 1.00 (0)              | 0.01    |
| PR+                            | 115 (30) | 0.85 (0.65–1.13)     |         |
| PR unknown                     | 152 (40) | 1.27 (0.98–1.65)     |         |
| **Sites of metastasis**        |         |                       |         |
| Presence of liver metastasis (vs none) | 148 (39) | 1.33 (1.07–1.66)     | 0.01    |
| Presence of brain metastasis (vs none) | 12 (3)   | 2.53 (1.37–4.67)     | 0.003   |
| Presence of lung metastasis (vs none) | 123 (33) | 1.40 (1.11–1.75)     | 0.004   |
| Presence of bone metastasis (vs none) | 256 (68) | 0.94 (0.75–1.17)     | 0.57    |
| Haemoglobin ≤ 12g dl⁻¹          | 132 (35) | 1.23 (0.99–1.53)     | 0.07    |
| Neutrophil > 7.5 × 10⁹ l⁻¹      | 46 (13)  | 1.88 (1.36–2.60)     | <0.001  |
| Bilirubin > 15 µmol l⁻¹         | 26 (7)   | 1.89 (1.24–2.87)     | 0.003   |
| Alkaline phosphatase > 125 IU l⁻¹ | 199 (54) | 1.31 (1.05–1.62)     | 0.02    |
| **(B) Baseline QL* (LASA variables)** |         |                       |         |
| Physical well-being (PWB)      |         |                       | <0.0001 |
| Mid PWB (vs good PWB)          | 142 (40) | 1.70 (1.33–2.18)     |         |
| Poor PWB (vs good PWB)         | 63 (18)  | 2.04 (1.50–2.78)     |         |
| Appetite                       |         |                       | <0.0001 |
| Mid appetite (vs good appetite) | 88 (25)  | 1.60 (1.23–2.08)     |         |
| Poor appetite (vs good appetite) | 44 (13)  | 2.10 (1.50–2.93)     |         |
| Overall QL                     |         |                       | 0.0001  |
| Mid overall (vs good overall)  | 142 (42) | 1.71 (1.34–2.19)     |         |
| Poor overall (vs good overall) | 37 (11)  | 1.41 (0.96–2.06)     |         |
| Mood                           |         |                       | 0.01    |
| Mid mood (vs good mood)        | 151 (43) | 1.44 (1.13–1.83)     |         |
| Poor mood (vs good mood)       | 48 (14)  | 1.31 (0.94–1.84)     |         |
| Pain                           |         |                       | 0.08    |
| Mid pain (vs good pain)        | 113 (32) | 1.16 (0.90–1.49)     |         |
| Poor pain (vs good pain)       | 63 (18)  | 1.41 (1.05–1.91)     |         |
| Nausea/vomiting                |         |                       | 0.21    |
| Mid nausea/vomiting (vs good nausea/vomiting) | 49 (14)  | 1.30 (0.95–1.77)     |         |
| Poor nausea/vomiting (vs good nausea/vomiting) | 14 (4)   | 1.29 (0.73–2.28)     |         |

Abbreviations: CI = confidence interval; ER = oestrogen receptor; LASA = linear analogue self-assessment; PR = progesterone receptor; QL = quality of life. *Good QL = LASA score 0–25, Mid QL = LASA score 26–65, Poor QL = LASA score 66–100.
who achieved a complete response (CR) or partial response (PR). Weight loss (vs stable or weight gain) was measured as the proportion of patients with an average decrease in weight from their baseline reading.

Treatment toxicity

Adverse events (AEs) were expressed as the proportion of patients who developed any grade 3 or grade 4 toxicity during the first 4 cycles of chemotherapy treatment. World Health Organisation criteria (Miller et al, 1981) were used for ANZ8101 and ANZ8614; National Cancer Institute Common Toxicity Criteria (Arbuck et al, 1998) were used for ANZ0001. Haematological (anaemia, neutropenia and thrombocytopenia) and non-haematological (nausea, vomiting, diarrhoea, stomatitis and alopecia) AEs were analysed separately.

Statistical analysis

Overall survival and PFS were estimated by the Kaplan–Meier method, and differences between patients with good, mid and poor levels for each QL scale at baseline were compared with the log-rank test (Kaplan and Meier, 1958). Cox proportional-hazard models were used to estimate differences in OS according to each level of the QL scale (Cox, 1972). Multivariable analysis for OS was first performed with backward stepwise selection of biomedical variables only. Then, multivariable analysis for OS was repeated with backward stepwise selection of biomedical and QL variables. Only statistically significant variables (P<0.05) were retained in the final multivariable models. As shown in a previous analysis using the same data set (Lee et al, 2010), trial is a significant factor for survival; thus we stratified for trial in all univariable and multivariable analyses for this study. Formal tests to detect the presence of collinearity between the different QL scales, and QL scales and ECOG performance status were also performed (Weissfeld, 1989).

Univariable analyses with logistic regression tested for associations between QL subscales and OTR, AE and weight loss. Multivariable models for these outcomes were constructed to estimate the effects of these QL subscales, adjusted for biomedical variables found to be significant in Cox model for OS. All analyses were two-sided with no adjustment for multiple comparisons. No imputation of missing baseline QL values was performed.

RESULTS

Biomedical and demographic characteristics

A total of 378 patients with a median follow-up of 4.8 years were included in this pooled analysis. The number of patients from ANZ8101, ANZ8614 and ANZ0001 were 75 (20%), 194 (51%) and 109 (29%), respectively. The median follow-up of these patients from ANZ8101, ANZ8614 and ANZ0001 were 4.8 years (range 0–4.8 years), 10.1 years (range 0–10.9 years) and 3.2 years (range 0–4.8 years), respectively. Table 1 summarises the baseline characteristics and the treatment profiles of these patients for the overall cohort and according to the baseline PWB. Apart from performance status and lung metastasis, distribution of baseline characteristics was similar in patients with good, mid and poor PWB. Similar patterns of baseline characteristics were observed for other QL scales (data not shown).

Baseline QL scores

Baseline LASA scores for each QL scale were available for 89–94% of the patients. The proportion of patients with self-rating for each scale was 93% (PWB), 94% (mood), 93% (pain), 93% (nausea and vomiting), 93% (appetite) and 89% (overall life quality). The distribution of the three categories of LASA scores for each QL subscale is shown in Table 2B.

CMFP treatment

Two patients randomised to CMFP chemotherapy in the original trials did not receive the assigned treatment. The remaining 376 patients (99.5%) received a median five cycles of treatment. The chemotherapy doses administered were between 90 and 93% of those planned. Patients with good, mid and poor PWB received medians of 6, 5 and 3 cycles of CMFP, respectively (Table 1).

OS and PFS

Physical well-being, mood, appetite and overall QL were predictors of OS in the univariable analyses (Table 2B). Physical well-being and appetite were independent predictors of survival in a multivariable model with biomedical and QL variables (Table 3B). Performance status was statistically significant in a multivariate model with biomedical factors only (Table 3A), but was not statistically significant in a multivariable model with biomedical and QL scales (Table 3B). Patients with good PWB at baseline had a statistically significantly longer PFS and OS compared with patients who had mid or poor PWB (Figure 1A and B). The median OS for patients with good, mid and poor PWB were 19, 11 and 9 months, respectively (log-rank P<0.0001). Similar results were observed for patients with good, mid and poor appetite (Figure 1C and D).

Significant collinearity was not detected between the different QL scales or between QL scales and ECOG performance status (results not shown).

Table 3 Multivariable Cox regression analyses of survival for demographic and baseline clinical characteristics, and for baseline demographic and clinical characteristics and QL variables (n = 378)

| Hazard ratio (95% CI) | P-value |
|----------------------|---------|
| **(A) ’Best’ model with demographic and clinical characteristics only** |
| Age > 60 | 1.46 | (1.16–1.84) | 0.001 |
| ER− | 1.00 | — | 0.002 |
| ER+ | 0.63 | (0.47–0.84) | — |
| ER unknown | 0.94 | (0.70–1.25) | — |
| Neutrophil > 7.5 × 10^9 l^{−1} | 1.68 | (1.18–2.40) | 0.004 |
| PS 0 | 1.00 | — | 0.005 |
| PS1 | 1.44 | (1.11–1.88) | — |
| PS2 | 1.60 | (1.16–2.22) | — |
| PS3 & PS4 | 1.83 | (1.14–2.93) | — |
| Presence of brain metastasis (vs none) | 2.42 | (1.28–4.57) | 0.006 |
| Presence of liver metastasis (vs none) | 1.38 | (1.08–1.77) | 0.009 |
| Alkaline phosphatase > 125 IU l^{−1} | 1.31 | (1.03–1.67) | 0.03 |

| **(B) ’Best’ model with demographic, clinical characteristics and QL variables** |
| Neutrophil > 7.5 × 10^9 l^{−1} | 1.91 | (1.31–2.79) | 0.001 |
| Age > 60 | 1.45 | (1.14–1.83) | 0.002 |
| ER− | 1.00 | — | 0.004 |
| ER+ | 0.64 | (0.47–0.87) | — |
| ER unknown | 0.98 | (0.72–1.33) | — |
| Good PWB^ | 1.00 | — | 0.004 |
| Mid PWB^ | 1.45 | (1.09–1.91) | — |
| Poor PWB^ | 1.64 | (1.12–2.40) | — |
| Presence of brain metastasis (vs none) | 2.37 | (1.21–4.64) | 0.01 |
| Alkaline phosphatase > 125 IU l^{−1} | 1.37 | (1.08–1.74) | 0.01 |
| Good appetite^ | 1.00 | — | 0.03 |
| Mid appetite^ | 1.36 | (1.01–1.84) | — |
| Poor appetite^ | 1.49 | (0.98–2.24) | — |

Abbreviations: CI = confidence interval; ER = oestrogen receptor; PWB = physical well-being; PS = performance status; QL = quality of life; ULN = upper limit normal.
^Good PWB/appetite = LASA score 0–25; mid PWB/appetite = LASA score 26–65; poor PWB/appetite = LASA score 66–100.
**Objective tumour response**

The OTR rates for patients with good, mid and poor PWB were 47, 32 and 18%, respectively (adjusted $P_{\text{trend}} < 0.001$; Figure 2A). For patients with good, mid and poor appetite, the OTR rates were 41, 34 and 18% respectively (adjusted $P_{\text{trend}} = 0.02$; Figure 2A).

**Weight loss**

Fifty-one percent of women experienced weight loss during chemotherapy. Women with good PWB had a mean weight gain during chemotherapy of 2%, but mean weight loss was 2% for women with mid PWB and 4% for women with poor PWB.
Clinical Studies

Baseline QL, chemotherapy benefit and toxicity

CK Lee et al

1346

women with poor appetite (adjusted weight loss was 2% for women with mid appetite and 7% for good appetite, there was a mean weight gain of 0.5%, but mean PWB different in patients with good, mid and poor appetite (adjusted 4 alopecia rates were similar in the three PWB groups. 9, 12 and 11%; and grade-3 and 4 stomatitis in 8, 11 and 17% of nausea and vomiting were reported in 19, 41 and 42%; diarrhoea in grade-3 and 4 stomatitis in 8, 11 and 17% of patients with good, mid and poor PWB, respectively. Grade-3 and 4 alopecia rates were similar in the three PWB groups. The rates of non-haematological AEs were not significantly different in patients with good, mid and poor appetite (adjusted P_trend = 0.06; Figure 2B). Grade-3 and 4 haematological toxicity rates were not associated with PWB (adjusted P_trend = 0.92) or appetite scores (adjusted P_trend = 0.60).

TREATMENT TOXICITY

Non-haematological AE rates were statistically significantly different for patients with good (16%), mid (31%) and poor (38%) PWB (adjusted P_trend = 0.002; Figure 2C). Grade-3 or 4 nausea and vomiting were reported in 19, 41 and 42%; diarrhoea in 9, 12 and 11%; and grade-3 and 4 stomatitis in 8, 11 and 17% of patients with good, mid and poor PWB, respectively. Grade-3 and 4 alopecia rates were similar in the three PWB groups.

Our study also showed that women with poor QL derived less benefit and experienced more toxicity when treated with chemotherapy than women with good QL. Overall, women reporting poor QL at baseline received 50% fewer cycles of chemotherapy, were 20–30% less likely to benefit from chemotherapy and experienced rates of non-haematological treatment toxicity 20% higher than women reporting good QL at baseline.

This research adds to the growing evidence that QL is an independent predictor of survival in advanced cancer. In a systematic review of cancer trials, Gotay et al (2008) reported that 36 of 39 trials showed an association between QL and survival. Specific QL measures most frequently identified in these trials were overall QL, physical well being, appetite loss and pain. Another meta-analysis using data from 30 cancer trials produced a multivariable model that identified impaired physical functioning, pain and appetite loss as independent predictors of survival in addition to established biomedical factors (Quinten et al, 2009). Individual trials in advanced breast cancer have shown similar findings with PWB (Coates et al, 1992), appetite loss (Efficacce et al, 2004), pain (Kramer et al, 2000) and overall QL (Seidman et al, 1995; Winer et al, 2004) all reported as independent predictors of survival. This study validates the prognostic significance of self-reported QL, and specifically of PWB and appetite, as predictors of survival in advanced breast cancer.

Furthermore, our findings raise the important question of whether measurement of baseline QL can be used to improve the selection of patients for chemotherapy. To date, few studies have investigated baseline QL as predictor of treatment benefit and/or

DISCUSSION

In this analysis of women treated with CMFP as first-line chemotherapy for advanced breast cancer, patient self-reported PWB and appetite at baseline were independent predictors of OS and PFS. Women with poor PWB had a median OS that was 10 months shorter, and a median PFS that was 5 months shorter, than women with good PWB. Furthermore, women with poor PWB had OTR rates 29% lower, weight loss rates 19% lower and treatment-related non-haematological AE rates 22% higher than women with good PWB. Similar findings were observed for women with poor appetite compared with those who had good appetite.

Furthermore, we observed that women with poor QL had OTR rates 29% lower, weight loss rates 19% lower and treatment-related non-haematological AE rates 22% higher than women with good PWB. Similar findings were observed for women with poor appetite compared with those who had good appetite.

Our study also showed that women with poor QL derived less benefit and experienced more toxicity when treated with chemotherapy than women with good QL. Overall, women reporting poor QL at baseline received 50% fewer cycles of chemotherapy, were 20–30% less likely to benefit from chemotherapy and experienced rates of non-haematological treatment toxicity 20% higher than women reporting good QL at baseline.

This research adds to the growing evidence that QL is an independent predictor of survival in advanced cancer. In a systematic review of cancer trials, Gotay et al (2008) reported that 36 of 39 trials showed an association between QL and survival. Specific QL measures most frequently identified in these trials were overall QL, physical well being, appetite loss and pain. Another meta-analysis using data from 30 cancer trials produced a multivariable model that identified impaired physical functioning, pain and appetite loss as independent predictors of survival in addition to established biomedical factors (Quinten et al, 2009). Individual trials in advanced breast cancer have shown similar findings with PWB (Coates et al, 1992), appetite loss (Efficacce et al, 2004), pain (Kramer et al, 2000) and overall QL (Seidman et al, 1995; Winer et al, 2004) all reported as independent predictors of survival. This study validates the prognostic significance of self-reported QL, and specifically of PWB and appetite, as predictors of survival in advanced breast cancer.

Furthermore, our findings raise the important question of whether measurement of baseline QL can be used to improve the selection of patients for chemotherapy. To date, few studies have investigated baseline QL as predictor of treatment benefit and/or

Figure 2 (A) Proportion of OTR stratified by PWB and Appetite scores. (B) Proportion with weight loss during chemotherapy stratified by PWB and Appetite scores. (C) Proportion with grade-3/4 non-haematological toxicity stratified by PWB and Appetite scores (*QL adjusted for performance status, age, liver, and brain metastasis, oestrogen receptor status, neutrophil, serum alkaline phosphatase and trial enrolment).
toxicity in advanced breast cancer. Kramer et al (2000) reported an association between QL (dyspnoea, fatigue and overall QL) and tumour response in their analysis of 187 women treated with paclitaxel or doxorubicin, but selection of specific QL scales as independent predictors in the final multivariable model was reported as unstable because of multi-collinearity. They did not examine associations between QL and toxicity in this analysis. Two other studies reported no association between QL and tumour response to chemotherapy (Seidman et al, 1995; Winer et al, 2004) or treatment-related toxicity (Seidman et al, 1995). Possible explanations for the differences between these results and our study include small sample size (Seidman et al, 1995), the type of QL instruments and QL subscales used, and the methods used to assess tumour response.

The main strength of this study is the use of high-quality, individual patient data from three successive randomised clinical trials conducted by the same group. The pooled data set contains well-documented demographic, clinical and QL characteristics of trial participants who were treated with the same regimen of chemotherapy. Women in this study were assigned chemotherapy independent of their baseline QL. Follow-up and outcome data were collected prospectively with rigorous quality control.

This study has several limitations. First, our findings are from women with advanced breast cancer who were treated with CMFP. They may differ with other chemotherapy regimens or for other cancers (Quinten et al, 2009). Second, the results are not generalisable to women with early-stage breast cancer who do not have tumour-related symptoms (Coates et al, 2000; Goodwin et al, 2004; Gotay et al, 2008). Finally, this analysis was conducted post hoc using available trial data and therefore should be regarded as hypothesis-generating for future studies, rather than definitive.

If our findings are confirmed, trials of new treatment approaches should be investigated for women with poor QL. These trials could address the value of any chemotherapy vs none, of less intense vs standard-intensity chemotherapy, or of chemotherapeutic or biological agents with a more favourable therapeutic–toxic ratio. Outcomes, which incorporate both survival time and QL, such as quality-adjusted PFS and OS, may be more relevant measures of treatment benefit in these women. The results of this study also suggest the value of stratifying patients by their baseline QL for future randomised trials in advanced breast cancer.

The primary goal of chemotherapy in advanced breast cancer is to prolong and improve QL. Our findings suggest that women with poor QL derive less benefit from chemotherapy and have increased risks of toxicity than women with good QL. This analysis should be regarded as hypothesis-generating and future studies that examine the role of chemotherapy in advanced breast cancer patients with poor QL are warranted.

REFERENCES

Arbuck S, Ivy S, Setser A (1998) The Revised Common Toxicity Criteria: Version 2.0: CTEP Website. http://ctep.info.nih.gov
Coates A, Gebski V, Bishop J, Jeal P, Woods R, Snyder R, Tattersall M, Byrne M, Harvey V, Gill G (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. J Natl Cancer Inst 131: 1490 – 1495
Coates A, Gebski V, Signorini D, Murray P, McNeil D, Bryne M, Forbes J (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10: 1833 – 1838
Coates A, Thomson D, McLeod G, Hersey P, Gill PG, Olver IN, Kefford R, Lowenthal RM, Beadle G, Walpole E (1993) Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 29A: 1731 – 1734
Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, J Royal Stat Soc Cox DR (1972) Regression models and life-tables. 34: 263 – 279
Cox DT (1972) Regression models and life-tables. J Royal Stat Soc 34: 187 – 220
Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gunzmu T, Twelves C, Fargeot P, Bottomley A (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 34: 3768 – 3774
Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P, Simes RJ (2010) Prognostic factors in 1038 metastatic but not early breast cancer patients. Eur J Cancer 46: 541 – 548
Lee CK, Lord SJ, Stockler MR, Coates AS, Gebski V, Simes RJ (2010) Historical cross-trial comparisons for competing treatments in advanced breast cancer – an empirical analysis of bias. Eur J Cancer 36: 541 – 548
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207 – 214
Priestman T, Baum M, Jones V, Forbes J (1977) Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. Br Med J 1: 1248 – 1250
Quinten C, Coens C, Maurer M, Comte S, Sprangers MAG, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic predictor of survival: a meta-analysis of individual patient data from EORTC clinical trials. J Clin Oncol 18: 3768 – 3774
Seidman AD, Portenoy R, Yao T-J, Lepore J, Mont EK, Kortmansky J, Onetto N, Ren L, Grechko J, Beltangady M, Usakewicz J, Southrada M, Houston C, McCabe M, Salvaggio R, Thaler H, Norton L (1995) Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87: 1316 – 1322
Simes R, Gebski V, Coates A, Forbes J, Harvey V, Van Hazel G, Tattersall M, Abdi E, Brigham B (1994) Quality of life with single agent mitozantrone or combination chemotherapy for advanced breast cancer, a randomized trial. Proc Am Soc Clin Oncol 13: 73
Spitzer W, Dobson A, Hall J, Chesterton S, Levi J, Shepherd R, Battista RN, Catchlove BR (1981) Measuring the quality of life of cancer patients: a concise QL index for use by physicians. J Chronic Dis 34: 585 – 597
Stockler M, Mourjina T, Harvey V, Frances P, Byrne M, van Hazel G, Fitzharris B, Ackland S, Finch K, Lindsay D, Kato-Fong A, Paksec L, Gebski V, Simes R, Coates A, Forbes J (2007) A randomized trial of capcitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Res Treat 106: S278
Weissfeld LA (1989) A multicollinearity diagnostic for models fit to censored data. Commun Stat Theory Methods 18: 2073 – 2085
Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Fitzharris R, Hennessy I, Huda C, Musa H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22: 2061 – 2068